Truvestments Capital LLC Raises Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Truvestments Capital LLC grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 25.2% in the fourth quarter, Holdings Channel reports. The firm owned 1,847 shares of the medical equipment provider’s stock after acquiring an additional 372 shares during the period. Truvestments Capital LLC’s holdings in Intuitive Surgical were worth $964,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Berbice Capital Management LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth about $26,000. BankPlus Trust Department purchased a new stake in Intuitive Surgical in the fourth quarter worth about $28,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Intuitive Surgical in the fourth quarter worth about $31,000. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical in the third quarter worth about $33,000. Finally, Decker Retirement Planning Inc. purchased a new stake in Intuitive Surgical in the fourth quarter worth about $36,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $493.72 on Wednesday. Intuitive Surgical, Inc. has a 1 year low of $364.17 and a 1 year high of $616.00. The firm has a market capitalization of $175.85 billion, a price-to-earnings ratio of 77.02, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The business’s 50 day moving average price is $569.91 and its 200-day moving average price is $531.84.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Citigroup boosted their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Raymond James boosted their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Barclays upped their price objective on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Finally, Wells Fargo & Company upped their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the company an “overweight” rating in a report on Friday, January 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $613.10.

Insider Activity

In other news, SVP Mark Brosius sold 489 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $533.18, for a total transaction of $260,725.02. Following the transaction, the senior vice president now owns 2,091 shares in the company, valued at $1,114,879.38. This trade represents a 18.95 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Myriam Curet sold 408 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $589.75, for a total value of $240,618.00. Following the completion of the transaction, the executive vice president now owns 353 shares in the company, valued at $208,181.75. The trade was a 53.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,309 shares of company stock worth $7,611,004 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.